<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524326</url>
  </required_header>
  <id_info>
    <org_study_id>17-635</org_study_id>
    <nct_id>NCT03524326</nct_id>
  </id_info>
  <brief_title>Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase I/Ib Study of Lenvatinib and Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study, which tests the safety of different doses of lenvatinib in&#xD;
      combination with cetuximab, to see which dose is the safest in people. This study will help&#xD;
      find out if lenvatinib and cetuximab is a safe and useful combination for treating patients&#xD;
      with HNSCC and cSCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of Lenvatinib when combined with Cetuximab</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 3+3 dose de-escalation design for three dose levels of lenvatinib combined with cetuximab will be used. A DLT will be defined as any toxicities of grade 3 or higher (per CTCAE v4 criteria) felt to be possibly, probably, or definitely related to lenvatinib, as well as grade 4 toxcities related to cetuximab, which occurs within 28 days following the first dose of lenvatinib in combination with cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib Pill</intervention_name>
    <description>24 mg oral daily</description>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
    <other_name>Level 0 Lenvatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib Pill</intervention_name>
    <description>20 mg oral daily</description>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
    <other_name>Level -1 Lenvatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib Pill</intervention_name>
    <description>14 mg oral daily</description>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
    <other_name>Level -2 Lenvatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400mg/m2 IV, then 500mg/m2 IV weekly</description>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib Pill</intervention_name>
    <description>10 mg oral daily</description>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
    <other_name>Level -3 Lenvatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib Pill</intervention_name>
    <description>4 mg oral daily</description>
    <arm_group_label>Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma</arm_group_label>
    <other_name>Level -4 Lenvatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytologic diagnosis of squamous cell cancer&#xD;
&#xD;
          -  Clinical diagnosis of squamous cell cancer of the head and neck (non-nasopharynx&#xD;
             primary tumors: oral cavity, oropharynx, hypopharynx, larynx and sinonasal) or skin&#xD;
&#xD;
          -  HNSCC and cSCC cannot be curable by surgery and/or radiation therapy&#xD;
&#xD;
          -  Measureable disease as per RECIST v1.1, which includes locoregional lesions (not&#xD;
             amenable to curative surgery and/or radiation) and distant metastatic lesions&#xD;
&#xD;
          -  Blood pressure &lt; 150/90 at screening with or without antihypertensive medications and&#xD;
             no change in antihypertensive medications within 1 week prior to initiation of&#xD;
             treatment&#xD;
&#xD;
          -  ECOG Performance Status of 0-1&#xD;
&#xD;
          -  Adequate renal function as evidenced by calculated creatinine clearance &gt; 30 ml/min&#xD;
             according to the Cockcroft and Gault Formula or by 24 hour urine creatinine clearance&#xD;
&#xD;
          -  Adequate liver function as determined by (1) Bilirubin &lt; 1.5 x upper limit of normal&#xD;
             (ULN) except for unconjugated hyperbilirubinemia or Gilbert&quot;s syndrome; (2) ALT and&#xD;
             AST &lt; 3 x ULN (&lt;5 x ULN if subject has liver mets)&#xD;
&#xD;
          -  Adequate hematologic function as determined by (1) platelets &gt; 100,000; (2) Hemoglobin&#xD;
             &gt; 9 gm/dl; (3) absolute neutrophil count &gt; 1200&#xD;
&#xD;
          -  Adequate archival tissue to perform molecular analysis through MSK-IMPACT if&#xD;
             MSK-IMPACT has not been performed previously on the patient&quot;s tumor; if MSK-IMACT has&#xD;
             not been previously performed and adequate archival tissue is not available, a patient&#xD;
             should be agreeable to a pre-treatment biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior grade 3 hypersensitivity to cetuximab requiring discontinuation&#xD;
&#xD;
          -  Prior lenvatinib&#xD;
&#xD;
          -  Major surgery within 2 weeks of first dose of lenvatinib&#xD;
&#xD;
          -  Metastatic brain or leptomeningeal tumors (treated metastatic brain or leptomeningeal&#xD;
             tumors are allowed).&#xD;
&#xD;
          -  Anticancer treatment (e.g., radiation therapy, chemotherapy) within 21 days of first&#xD;
             dose&#xD;
&#xD;
             °An exception is cetuximab treatment, which can be received within 21 days of the&#xD;
             first treatment on study&#xD;
&#xD;
          -  No prior palliative radiation to a target lesion is allowed, unless there is clear&#xD;
             biopsy proven progression following radiation. Note, prior radiations to a non-target&#xD;
             lesion is allowed. Please see section 9.3.Subjects having a spot Urine&#xD;
             Protein:Creatinine ratio of &gt;1 will undergo 24-hour collection for quantitative&#xD;
             assessment of proteinuria. If urine protein &gt; 1 gram/24 hours, the subject will be&#xD;
             ineligible&#xD;
&#xD;
          -  Significant cardiovascular impairment within 6 months as defined as (1) congestive&#xD;
             heart failure greater than New York Heart Association Class II, (2) unstable angina,&#xD;
             (3) myocardial infarction; (4) stroke, (5) symptomatic cardiac arrhythmia&#xD;
&#xD;
          -  On electrocardiogram, QTc interval &gt; 500 msec&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to first dose&#xD;
             of lenvatinib&#xD;
&#xD;
          -  Other active malignancy except for basal cell or squamous cell carcinoma of the skin,&#xD;
             or carcinoma in situ of the cervix or bladder&#xD;
&#xD;
          -  Women who are breast feeding or pregnant ° Men or women of reproductive potential who&#xD;
             are not willing to employ effective birth control from screening to 30 days after the&#xD;
             last dose of study drugs; the definition of adequate contraception will be based on&#xD;
             the judgment of the principal investigator or a designated associate.&#xD;
&#xD;
        For a female patient to be considered as not of child bearing potential, she should fulfill&#xD;
        one of the following:&#xD;
&#xD;
        ° Post-menopausal women, defined as either women aged more than 50 years and amenorrhoeic&#xD;
        for at least 12 months following cessation of all exogenous hormonal treatments, or, women&#xD;
        under 50 years old who have been amenorrhoeic for at least 12 months following the&#xD;
        cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone&#xD;
        (FSH) and luteinizing hormone (LH) levels in the postmenopausal range for the institution.&#xD;
&#xD;
        Or&#xD;
&#xD;
        ° Have documentation of irreversible surgical sterilisation by hysterectomy, bilateral&#xD;
        oophorectomy or bilateral salpingectomy (but not tubal ligation)&#xD;
&#xD;
          -  Evidence of clinically significant disease (e.g., cardiovascular, respiratory,&#xD;
             gastrointestinal, renal disease) that in the opinion of the investigator could affect&#xD;
             the subject safety or interfere with the study assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara Dunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>Lenvatinib</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>17-635</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

